MannKind

MannKind Total Assets

The Total Assets of MannKind (MNKD) as of Oct 28, 2026 is 792.18 M USD. In the previous year, Total Assets was 393.84 M USD — a change of 101.14% (higher).

Total Assets

792.18 MUSD

YoY

101.14%

Last updated:

Total Assets of MannKind is 2025 792.18 M USD. Total Assets of MannKind was 2024 393.84 M USD. It decreases by 101.14% higher compared to the previous year.

The MannKind Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
107.71 M USD
Jan 1, 2019
93.73 M USD
Jan 1, 2020
108.61 M USD
Jan 1, 2021
321.16 M USD
Jan 1, 2022
295.28 M USD
Jan 1, 2023
475.20 M USD
Jan 1, 2024
393.84 M USD
Jan 1, 2025
792.18 M USD
The MannKind Total Assets history
YEARTotal AssetsYoY
792.18 MUSD+101.14%
393.84 MUSD-17.12%
475.20 MUSD+60.93%
295.28 MUSD-8.06%
321.16 MUSD+195.71%
108.61 MUSD+15.88%
93.73 MUSD-12.98%
107.71 MUSD+27.35%
84.58 MUSD-21.00%
107.06 MUSD-15.31%
126.41 MUSD-67.95%
394.44 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

Total Assets of MannKind is 792.18 M USD in 2025.

Total Assets of MannKind changed from 393.84 M USD to 792.18 M USD, representing a 101.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets MannKind since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's MannKind historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MannKind

All Key Metrics — MannKind